Global $196.96 Bn Oncology Devices Market to 2025 & 2030: Major Players are Eckert & Ziegler BEBIG, Oncura, GE, Medtronic, Varian Medical Systems, Elekta, Theragenics, Accuray, and Roche Diagnostics
August 20, 2021 06:08 ET
|
Research and Markets
Dublin, Aug. 20, 2021 (GLOBE NEWSWIRE) -- The "Oncology Devices Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering. The global...
Telix Progresses Novel Lung and Ovarian Cancer Theranostic APOMAB®
August 16, 2021 20:03 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and ADELAIDE, Australia, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces it has extended its previously...
Celsion Reports Data Safety Monitoring Board Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer
July 19, 2021 08:00 ET
|
Celsion CORP
OVATION 2 Study is 50% Enrolled; Excellent R0 Surgical Resection Noted Novel Gene-Mediated Immunotherapy is Safe and Demonstrates an Acceptable Risk/Benefit When Administered Over a Six-Month...
Immunicum tillkännager inkludering av den första patienten i fas I ALISON-studien som utvärderar vaccinkandidaten DCP-001 vid äggstockscancer
June 23, 2021 02:00 ET
|
Immunicum AB
Pressrelease 23 juni, 2021 Immunicum tillkännager inkludering av den första patienten i fas I ALISON-studien som utvärderar vaccinkandidaten DCP-001 vid äggstockscancer - Första studien för...
Immunicum Announces Enrollment of First Patient in Phase I ALISON Study Evaluating Cancer Relapse Vaccine Candidate DCP-001 in Ovarian Cancer
June 23, 2021 02:00 ET
|
Immunicum AB
Press Release 23 June 2021 Immunicum Announces Enrollment of First Patient in Phase I ALISON Study Evaluating Cancer Relapse Vaccine Candidate DCP-001 in Ovarian Cancer - First study...
CELSION CORPORATION ANNOUNCES ADJOURNMENT OF ANNUAL MEETING
June 04, 2021 10:11 ET
|
Celsion CORP
49% of Shares Voted, Quorum Not Established To Hold Annual Meeting Polls Remain Open Stockholders Holding Unvoted Proxies Are Strongly Encouraged to Vote Their Shares LAWRENCEVILLE, N.J.,...
Phase 2b VITAL study of Gemogenovatucel-T (Vigil™) immunotherapy demonstrates clinical benefit in homologous recombination (HR) proficient ovarian cancer
March 26, 2021 11:41 ET
|
Gradalis, Inc.
Results from pre-planned subgroup analysis of stage III/IV newly diagnosed ovarian cancer patients with BRCA wild type (BRCA-wt) profile and homologous recombination proficiency (HRP) have been...
Gradalis Announces Publication of Phase 2b VITAL trial of Vigil® demonstrating RFS and OS advantage in women with first-line platinum-responsive BRCA1 and BRCA2 wild-type advanced ovarian cancer in The Lancet Oncology
January 07, 2021 07:00 ET
|
Gradalis, Inc.
The VITAL study, published in The Lancet Oncology, demonstrates that Vigil first-line maintenance treatment resulted in improved RFS in BRCA1/2-wt ovarian cancer when compared to placebo.Importantly...
Global $136.7 Billion Oncology Market to 2025
October 30, 2020 03:13 ET
|
Research and Markets
Dublin, Oct. 30, 2020 (GLOBE NEWSWIRE) -- The "Oncology Market - Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering. Oncology Market size was valued at $136.7...
THE NATIONAL OVARIAN CANCER COALITION TO HOST ITS ANNUAL TOGETHER IN TEAL® - NO BOUNDARIES NATIONAL BROADCAST CELEBRATION DURING SEPTEMBER AWARENESS MONTH ON SATURDAY, SEPTEMBER 26, 2020
August 28, 2020 11:00 ET
|
National Ovarian Cancer Coalition
Dallas, Texas, Aug. 28, 2020 (GLOBE NEWSWIRE) -- DALLAS, TX August 28, 2020 —September is National Ovarian Cancer Awareness Month. The National Ovarian Cancer Coalition (NOCC) is tirelessly working...